Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydroxychloroquine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 known ✓ | Q9NR96 | 1/20 | 0.98 |
| ▸ | TLR7 known ✓ | Q9NYK1 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.98 |
| ▸ | LMNA | P02545 | 3/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.98 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.98 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.98 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.98 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.98 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.98 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.98 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.98 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxychloroquine SCHEMBL6746375 | 0.99 | CHRM2 (1.00) | KCNH2LMNACHRM2CHRM4CHRM5 | |
| Hydroxychloroquine SCHEMBL29430237 | 0.99 | CHRM2 (1.00) | KCNH2LMNACHRM2CHRM4CHRM5 | |
| Hydroxychloroquine SCHEMBL30107680 | 0.99 | CHRM2 (1.00) | KCNH2LMNACHRM2CHRM4CHRM5 | |
| Hydroxychloroquine SCHEMBL8623049 | 0.99 | CHRM2 (1.00) | KCNH2LMNACHRM2CHRM4CHRM5 | |
| Hydroxychloroquine SCHEMBL9047 | 0.99 | CHRM2 (1.00) | KCNH2LMNACHRM2CHRM4CHRM5 | |
| Hydroxychloroquine SCHEMBL29359553 | 0.99 | CHRM2 (1.00) | KCNH2LMNACHRM2CHRM4CHRM5 | |
| Hydroxychloroquine SCHEMBL8170 | 0.99 | CHRM2 (1.00) | KCNH2LMNACHRM2CHRM4CHRM5 | |
| Hydroxychloroquine SCHEMBL31023589 | 0.99 | CHRM2 (1.00) | KCNH2LMNACHRM2CHRM4CHRM5 | |
| Hydroxychloroquine SCHEMBL23854335 | 0.98 | CHRM2 (0.98) | KCNH2LMNACHRM2CHRM4CHRM5 | |
| Hydroxychloroquine SCHEMBL4204503 | 0.98 | CHRM2 (0.98) | KCNH2LMNACHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097593-B1 | Lipid A and other carbohydrate ligand analogs | ONCOTHYREON INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20120003295-A1 | LIPID A AND OTHER CARBOHYDRATE LIGAND ANALOGS | ONCOTHYREON INC. (US) | 2012-01-05 | — | — | US | disclosed |
| EP-1572918-B1 | SYNTHETIC GLYCO-LIPO-PEPTIDES AS VACCINES | ONCOTHYREON INC (US) | 2011-10-19 | — | — | EP | disclosed |
| US-7820627-B2 | Lipid A and other carbohydrate ligand analogs | ONCOTHYREON INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7741297-B2 | Immunostimulatory, covalently lipidated oligonucleotides | ONCOTHYREON INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1549322-B1 | LIPID A AND OTHER CARBOHYDRATE LIGAND ANALOGS | ONCOTHYREON INC (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20060189550-A1 | Immunostimulatory, Covalently lipidated oligonucleotides | BIOMIRA INC. (CA) | 2006-08-24 | — | — | US | disclosed |
| EP-1549322-A4 | LIPID A AND OTHER CARBOHYDRATE LIGAND ANALOGS | BIOMIRA INC (CA) | 2006-07-26 | — | — | EP | disclosed |
| US-20060116331-A1 | Glycosylceramide analogues | BIOMIRA, INC. (CA) | 2006-06-01 | — | — | US | disclosed |
| US-20060069238-A1 | Synthetic glyco-lipo-peptides as vaccines | BIOMIRA, INC. (CA) | 2006-03-30 | — | — | US | disclosed |
| EP-1429785-A4 | IMUNOGENIC CONJUGATE OF CARBOHYDRATE HAPTENS AND AGGREGATED PROTEIN CARRIER | BIOMIRA INC (CA) | 2005-12-14 | — | — | EP | disclosed |
| EP-1572114-A2 | GLYCOSYLCERAMIDE ANALOGUES | BIOMIRA, INC. (CA) | 2005-09-14 | — | — | EP | disclosed |
| EP-1549322-A2 | LIPID A AND OTHER CARBOHYDRATE LIGAND ANALOGS | BIOMIRA, INC. (CA) | 2005-07-06 | — | — | EP | disclosed |
| US-20040247608-A1 | Imunogenic conjugate of carbohydrate haptens and aggregated protein carrier | BIOMIRA INC. (CA) | 2004-12-09 | — | — | US | disclosed |
| EP-1474432-A1 | IMMUNOSTIMULATORY, COVALENTLY LIPIDATED OLIGONUCLEOTIDES | Biomira Inc. (CA) | 2004-11-10 | — | — | EP | disclosed |
| EP-1429785-A1 | IMUNOGENIC CONJUGATE OF CARBOHYDRATE HAPTENS AND AGGREGATED PROTEIN CARRIER | BIOMIRA, INC. (CA) | 2004-06-23 | — | — | EP | disclosed |
| WO-2004028475-A2 | GLYCOSYLCERAMIDE ANALOGUES | BIOMIRA, INC. (CA) | 2004-04-08 | — | — | WO | disclosed |
| WO-2003094850-A2 | LIPID A AND OTHER CARBOHYDRATE LIGAND ANALOGS | BIOMIRA, INC. (CA) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003066649-A1 | IMMUNOSTIMULATORY, COVALENTLY LIPIDATED OLIGONUCLEOTIDES | BIOMIRA INC. (CA) | 2003-08-14 | — | — | WO | disclosed |
| WO-2003015796-A1 | IMUNOGENIC CONJUGATE OF CARBOHYDRATE HAPTENS AND AGGREGATED PROTEIN CARRIER | BIOMIRA, INC. (CA) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069238-A1 | Synthetic glyco-lipo-peptides as vaccines | MUC1, LNPEP, LGALS1 | TLR9 384/4885TLR7 811/4885KCNH2 3873/4885 |
| US-20120003295-A1 | LIPID A AND OTHER CARBOHYDRATE LIGAND ANALOGS | SELPLG, STT3A, LY96 | TLR9 82/4885TLR7 117/4885KCNH2 2921/4885 |
| US-20060189550-A1 | Immunostimulatory, Covalently lipidated oligonucleotides | TLR9, TLR3, STING1 | TLR9 1/4885TLR7 9/4885KCNH2 4591/4885 |
| US-20060116331-A1 | Glycosylceramide analogues | UGCG, ASAH2, GBA2 | TLR9 742/4885TLR7 1127/4885KCNH2 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.